Notably, nuclear zinc was also found to be essential for BCR‐ABL transcriptional activity and mRNA stability, suggesting the potential benefit of low nuclear zinc in BCR‐ABL+ CML or ALL.[68]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.